KRAS and non-small cell lung carcinoma: In the MISSION trial, a phase III multicenter, placebo-controlled study that tested sorafenib in patients with relapsed or refractory non-squamous NSCLC after 2 or 3 previous chemotherapy regimens, PFS but not OS was significantly longer in both mutated and wild type-KRAS patients [99].